Session Abstract – PMWC 2021 Silicon Valley


The PMWC 2021 Liquid Biopsy Showcase will provide a 15-minute time slot for selected liquid biopsy companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies that advance the development of screening tests for oncology, immunotherapy, and other areas, based on detection and identification of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), circulating RNA, circulating microRNAs, or extracellular vesicle (exosomes).


Confirmed Presenting Companies:

 Session Chair Profile

Ph.D., Chief Scientific Officer, Covance, Sr VP, LabCorp

Biography
Dr Anderson has been with the LabCorp organization for 26 years and has held a variety of positions including director of operations for ViroMed Laboratories, director of operations for Monogram Biosciences, director of operations for the Center for Molecular Biology and Pathology, director of operations for Integrated Oncology and Genetics, national director of Research and Development, and global head of LabCorp Clinical Trials. Dr Anderson is a member of a variety of professional societies including the American Association for Cancer Research, the American Society of Clinical Oncology and the Association for Molecular Pathology. Dr Anderson’s research interests are in the development and applications for molecular diagnostics, including several examples of companion diagnostics and pharmacogenomics assays. He has authored more than 175 articles and abstracts published in such journals as Genetics, Proceedings of the National Academy of Sciences, Clinical Chemistry, the Journal of Infectious Disease, Human Pathology, American Journal of Obstetrics and Gynecology, Oncogene, the Journal of the National Cancer Institute, Clinical Cancer Research, Breast Cancer Research, BMC Cancer, the Journal of Molecular Diagnostics, Archives of Pathology and Laboratory Investigation and Expert Reviews in Molecular Diagnostics.


 Speaker Profile

Executive Chairman & CEO, Nucleix

Biography
Chris Hibberd has more than 20 years of diagnostics and biopharmaceutical experience in company formation, clinical and business development and commercialization. Prior to taking the helm of Nucleix, he was CEO and co-founder of Astute Medical. He managed a team and secured funding to support a product pipeline that included the launch of NephroCheck®, the first FDA cleared diagnostic for acute kidney injury risk, until its acquisition by bioMérieux. Prior to Astute Medical, he was SVP of corporate development at Biosite, where he managed business development activities that included cofounding Biosite Discovery, a world-class antibody capabilities collaboration, and Biosite’s $1.7 billion acquisition by Inverness Medical. Prior to that, he was a manager at The Boston Consulting Group and a development engineer at Albright & Wilson Americas. He obtained an MBA from the University of Western Ontario and a B.A.Sc. in chemical engineering from the University of Toronto.


Liquid Biopsy Showcase:
Nucleix

Nucleix is revolutionizing cancer treatment by leveraging its highly sensitive PCR and NGS-based EpiCheck® platform to find crucial markers and develop cost-effective screening tests for bladder and lung cancers – helping detect cancer earlier and potentially provide long-term benefit for patients.

EpiCheck®, Cancer Detection At The Earliest Moment
Sensitivity is crucial for early cancer detection. In this talk, Nucleix will outline how it leverages its highly sensitive PCR and NGS-based platforms to find the most important markers and then develop cost-effective PCR-based cancer screening tests for bladder and lung cancers. Highly sensitive tests in cancers like Lung Cancer have the potential to increase screening compliance and drive more patients to treatment when it has the greatest chance of providing long-term benefit.